Betty Chang - Summit Therapeutics Oncology Research
| SMMT Stock | USD 18.46 0.48 2.53% |
Executive
Betty Chang is Oncology Research of Summit Therapeutics PLC
| Address | 601 Brickell Key Drive, Miami, FL, United States, 33131 |
| Phone | 650 460 8308 |
| Web | https://www.summittxinc.com |
Summit Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3147) % which means that it has lost $0.3147 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7321) %, meaning that it created substantial loss on money invested by shareholders. Summit Therapeutics' management efficiency ratios could be used to measure how well Summit Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -2.91 in 2024. Return On Capital Employed is likely to drop to -0.52 in 2024. At this time, Summit Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 110.1 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 11 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ashraf Amanullah | Inhibrx | 56 | |
| MD MBA | Eliem Therapeutics | 50 | |
| Brendan Eckelman | Inhibrx | 45 | |
| Charbel PharmD | Inhibrx | N/A | |
| Jeffrey Jensen | Inhibrx | N/A | |
| Anne DVM | Molecular Partners AG | N/A | |
| Helen MD | Enliven Therapeutics | 61 | |
| Josep Garcia | Inhibrx | N/A | |
| Renate Gloggner | Molecular Partners AG | 54 | |
| Daniel Steiner | Molecular Partners AG | N/A | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Bonne MBA | Inhibrx | 47 | |
| Pamela Trail | Molecular Partners AG | 68 | |
| Zamaneh MD | Tff Pharmaceuticals | 60 | |
| MD MBA | Molecular Partners AG | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Carlos Bais | Inhibrx | N/A | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| David MBA | Inhibrx | N/A | |
| Dr Esq | Enliven Therapeutics | 47 | |
Management Performance
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.31 |
Summit Therapeutics PLC Leadership Team
Elected by the shareholders, the Summit Therapeutics' board of directors comprises two types of representatives: Summit Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Summit. The board's role is to monitor Summit Therapeutics' management team and ensure that shareholders' interests are well served. Summit Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Summit Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elaine JD, Head Counsel | ||
| Fong Clow, Chief Officer | ||
| Betty Chang, Oncology Research | ||
| Bhaskar Anand, Chief Finance | ||
| Robert Duggan, CoCEO Chairman | ||
| Manmeet Soni, COO Director | ||
| Will Black, Head Technology | ||
| Laura MD, Senior Development | ||
| Campbell Hair, Head HR | ||
| FRS DBE, Chairman CoFounder | ||
| DDS MBA, Pres CoCEO | ||
| Anne Heatherington, Head Sciences | ||
| Dave Gancarz, Chief Officer | ||
| Ankur Dhingra, Chief Officer | ||
| Manmeet CPA, CFO COO | ||
| Shelley Spray, Chief Officer | ||
| Juthamas Sukbuntherng, Head DMPK | ||
| Andrew Dwyer, Head Chain | ||
| Michelle Avery, Director Relations | ||
| Urte Gayko, Quality Regulatory | ||
| Divya Chari, Head Operations | ||
| MBA DDS, President CoCEO | ||
| Noam MBA, Senior Affairs | ||
| Abby Murphy, Head Resources |
Summit Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Summit Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 13.51 B | ||||
| Shares Outstanding | 737.45 M | ||||
| Shares Owned By Insiders | 84.36 % | ||||
| Shares Owned By Institutions | 11.75 % | ||||
| Number Of Shares Shorted | 15.99 M | ||||
| Price To Earning | 2.85 X | ||||
| Price To Book | 31.89 X | ||||
| Price To Sales | 753.90 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.